Expression of p53 oncoprotein in non-small-cell lung cancer: A favorable prognostic factor

Journal of Clinical Oncology

Volumn 13, Issue 8, 1995, Pages 1893-1903

  Lee, Jin Soo ^a   Yoon, Anthony ^a   Kalapurakal, Shyla K ^a   Ro, Jae Y ^a   Lee, J Jack ^a   Tu, Nora ^a   Hittelman, Walter N ^a   Hong, Waun K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0029113707     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1995.13.8.1893     Document Type: Article

References (52)

1. Boring CC, Squires TS, Tong T: Cancer statistics, 1994. CA 44:7-26, 1994
2. Lee JS, Hong WK: Prognostic factors in lung cancer. N Engl J Med 327:47-48, 1992
3. Hollstein M, Sidransky D. Vogelstein B: p53 mutations in human cancers. Science 253:49-53, 1991
4. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 351:453-456, 1991
5. Tominaga O, Hamelin R, Remvikos Y, et al: p53 from basic research to clinical applications. Crit Rev Oncogenesis 3:257-282, 1992
6. Chiba I, Takahashi T, Nau MM, et al: Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5:1603-1610, 1990
7. Kishimoto Y, Murakami Y, Shiraishi M, et al: Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 52:4799-4804, 1992
8. Mitsudomi T, Oyama T, Kusano T, et al: Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J Natl Cancer Inst 85:2018-2023, 1993
9. Horio Y, Takahashi T, Kuroishi T, et al: Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53:1-4, 1993
10. Marchetti A, Buttitta F, Merlo G, et al: p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 53:2846-2851, 1993
11. Carbone DP, Mitsudomi T, Rusch V, et al: p53 gene overexpression, but not gene mutation, is predictive of significantly shorter survival in resected non-small cell lung cancer (NSCLC) patients. Proc Am Soc Clin Oncol 12:334, 1993 (abstr)
12. Mitsudomi T, Steinberg SM, Nau, MM, et al: p53 mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171-180, 1992
13. Quinlan DC, Davidson AG, Summers CL, et al: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828-4831, 1992
14. McLaren R, Kuzu I, Dunnill M, et al: The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735-738, 1992
15. Brambilla E, Gazzeri S, Moro D, et al: Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 143:199-220, 1993
16. Morkve O, Halvorsen OJ, Skjaerven R, et al: Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas. Anticancer Res 13:571-578, 1993
17. Ebina M, Steinberg SM, Mulshine JL, et al: Relationship of p53 overexpression and upregulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 54:2496-2503, 1994
18. Passlick B, Izbicki JR, Riethmuller G, et al: p53 in non-small cell lung cancer. J Natl Cancer Inst 86:801-802, 1994
19. Altman DG, Lausen B, Sauerbrei W, et al: Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829-835, 1994
20. Lee JS, Ro JY, Sahin AA, et al: Expression of blood-group antigen A - A favorable prognostic factor in non-small cell lung cancer. N Engl J Med 324:1084-1090, 1991
21. Vojtesek B, Bartek J, Midgley CA, et al: An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237-244, 1992
22. Cattoretti G, Pileri S, Parravicini C, et al: Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 171:83-93, 1993
23. Caamano J, Ruggeri B, Momiki S, et al: Detection of p53 in primary lung tumors and nonsmall cell lung carcinoma cell lines. Am J Pathol 139:839-845, 1991
24. Park DJ, Nakamuro H, Chumakov AM, et al: Transcriptional and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 9:1899-1906, 1994
25. Scheffner M, Munger K, Byrne JC, et al: The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 88:5523-5527, 1991
26. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-81, 1958
27. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
28. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
29. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 69:239-241, 1982
30. Xu H-J, Quinlan DC, Davidson AG: Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst 86:692-699, 1994
31. Carbone DP: Molecular biology in the diagnosis and therapy of lung cancer, in ASCO Educational Book 1994. Chicago, IL, American Society of Clinical Oncology, 1994, pp 322-332
32. Tos APD, Doglioni C, Laurino L, et al: p53 protein expression in nonneoplastic lesions and benign and malignant neoplasms of soft tissue. Histopathology 22:45-50, 1993
33. Harris CC, Hollstein M: Clinical implications of the p53 tumor suppressor gene. N Engl J Med 329:1318-1327, 1993
34. Bodner SM, Minna JD, Jensen SM, et al: Expression of p53 proteins in lung cancer correlates with the class of p53 gene mutations. Oncogene 7:743-749, 1992
35. Battifora H: p53 immunochemistry: A word of caution. Hum Pathol 25:435-436, 1994
36. Kastan MB, Radin AI, Kuerbitz SJ, et al: Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res 51:4279-4286, 1991
37. Kastan MB, Onyekwere O, Sidransky D, et al: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991
38. Maltzman W, Czyzyk L: UV irradiation stimulates levels of p53 cellular tumor antigen in non-transformed mouse cells. Mol Cell Biol 4:1689-1694, 1984
39. Campbell C, Quinn AG, Angus B, et al: Wavelength-specific patterns of p53 induction in human skin following exposure to UV radiation. Cancer Res 53:2697-2699, 1993
40. Hall PA, McKee PH, Menage HP, et al: High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8:203-207, 1994
41. Levine AJ, Perry ME, Chang A, et al: The 1993 Walter Hubert lecture: The role of p53 tumor suppressor gene in tumorigenesis. Br J Cancer 69:409-416, 1994
42. Cho U, Gorina S, Jeffrey P, et al: Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265:346-355, 1994
43. Miller CW, Chumakov A, Said J, et al: Mutant p53 molecules have diverse intracellular abilities to oligomerize and activate transcription. Oncogene 8:1815-1824, 1993
44. Hinds PW, Finlay CA, Quartin RS, et al: Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: A comparison of the "hot spot" mutant phenotypes. Cell Growth Differ 1:571-580, 1990
45. Zhang W, Funk WD, Wright WE, et al: Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 8:2555-2559, 1993
46. Callahan R: p53 mutations, another breast cancer prognostic factor. J Natl Cancer Inst 84:826-827, 1992
47. Yamaguchi A, Kurosaka Y, Fushida S, et al: Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 70:2778-2784, 1992
48. Sun XF, Carstensen JM, Zhang H, et al: Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinomas. Lancet 340:1369-1373, 1992
49. Bosari S, Viale G, Bossi P, et al: Cytoplasmic accumulation of p53 protein: An important prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 86:681-687, 1994
50. Shin DM, Lee JS, Choi G, et al: Prognostic significance of p53 expression in head and neck squamous cell carcinoma (HNSCC). Proc Am Soc Clin Oncol 13:283, 1994 (abstr)
51. Esrig D, Elmajian D, Groshen S, et al: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331:1259-1264, 1994
52. Lane DP: p53, guardian of the genome. Nature 358:15-16, 1992